Pliva Opens New Oral Solid Forms Facility
Pliva?s new Oral Solid Forms Facility will increase Pliva's production capacities for tablets and capsules.
Pliva's new oral solid forms facility at its production site in Zagreb will increase Pliva's production capacities for tablets and capsules in addition to increasing exports as the majority of these products are intended for international markets. The $100 million investment also covers the transfer of the existing pilot plant for tablets to the new facility and an increase of production capacities for sterile forms.
This new facility will raise Pliva's and Teva's annual capacity by 2 billion tablets or more than 25%. Medicinal products manufactured in the new production facility are intended for EU and US markets, and commercial production will start as soon as the facility is approved by the FDA and other regulatory agencies.
Source: Pliva
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
